Pfizer (NYSE:PFE) and its partner BioNTech SE (NSDQ:BNTX) aim to expand the recent FDA approval of their COVID-19 vaccine to include booster doses for individuals 16 and older.
The companies have submitted a supplemental Biologics License Application to the FDA, including Phase 3 data drawn from participants aged 15 to 55.
The latest data indicate that a third dose of the Comirnaty vaccine boosts antibody titers and continues to be well tolerated.
Get the full story from our sister site, Drug Discovery & Development.